case_images: PMC10353895_01
case_images: (a) Multiple skin-colored translucent papules on the periorbital regions and cheeks. (b) Nine months after surgical therapy, the lesions on the lower eyelids do not obscure her vision. (c) The lesions have improved six months after laser therapy, even though partial scarring and hypopigmentation remain. (d) The persistence of the effect for CO2 FS was considered to be constant for at least three years.
case_images: CRIDM2023-6318220.001.jpg
case_images: PMC10353895_01_CRIDM2023-6318220.001.jpg
case_images: fig1
case_images: A physical examination revealed numerous dome-shaped, skin-colored, translucent lesions up to 2 mm in diameter on the periorbital regions and both cheeks (Figure 1(a)). After surgery, the patient's vision was no longer obscured (Figure 1(b)). At approximately six months and three years of follow-up, the symptoms showed continued improvement, and the cosmetic results were satisfactory, although some minor scarring and hypopigmentation persisted (Figures 1(c) and 1(d)).
case_images: Magnetic resonance image of the face shows 1 to 2 mm papules within the dermis, which exhibit a low intensity on T1-weighted imaging and a high intensity on T2-weighted imaging.
case_images: CRIDM2023-6318220.002.jpg
case_images: PMC10353895_01_CRIDM2023-6318220.002.jpg
case_images: fig2
case_images: Magnetic resonance imaging revealed 1 to 2 mm papules within the dermis, which exhibited a low and high intensity on T1- and T2-weighted imaging, respectively (Figure 2).
case_images: Unilocular cystic structure within the dermis on staining with hematoxylin-eosin. The lining of the cysts shows an inner layer of apocrine cells and an outer layer of myoepithelial cells. (a) x40 magnification. (b) x100 magnification.
case_images: CRIDM2023-6318220.003.jpg
case_images: PMC10353895_01_CRIDM2023-6318220.003.jpg
case_images: fig3
case_images: The inner layer of the cysts was lined by a row of columnar secretory cells peripheral to the layer lined by flattened myoepithelial cells (Figure 3).